These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 15623646

  • 1. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
    DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR, Damle NK.
    Clin Cancer Res; 2004 Dec 15; 10(24):8620-9. PubMed ID: 15623646
    [Abstract] [Full Text] [Related]

  • 2. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK.
    Clin Cancer Res; 2006 Jan 01; 12(1):242-9. PubMed ID: 16397048
    [Abstract] [Full Text] [Related]

  • 3. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
    DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK.
    Blood; 2004 Mar 01; 103(5):1807-14. PubMed ID: 14615373
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
    Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK.
    Leukemia; 2007 Nov 01; 21(11):2240-5. PubMed ID: 17657218
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES.
    Cancer Res; 1991 Nov 01; 51(21):5876-80. PubMed ID: 1933855
    [Abstract] [Full Text] [Related]

  • 6. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
    DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK.
    Cancer Immunol Immunother; 2005 Jan 01; 54(1):11-24. PubMed ID: 15693135
    [Abstract] [Full Text] [Related]

  • 7. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [Abstract] [Full Text] [Related]

  • 8. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 9. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
    Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H.
    Clin Cancer Res; 2005 May 15; 11(10):3879-88. PubMed ID: 15897589
    [Abstract] [Full Text] [Related]

  • 10. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
    Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM.
    Clin Cancer Res; 2008 Oct 01; 14(19):6154-60. PubMed ID: 18829494
    [Abstract] [Full Text] [Related]

  • 11. CD22 as a target of passive immunotherapy.
    Cesano A, Gayko U.
    Semin Oncol; 2003 Apr 01; 30(2):253-7. PubMed ID: 12720147
    [Abstract] [Full Text] [Related]

  • 12. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
    de Kroon JF, de Paus RA, Kluin-Nelemans HC, Kluin PM, van Bergen CA, Munro AJ, Hale G, Willemze R, Falkenburg JH.
    Exp Hematol; 1996 Jul 01; 24(8):919-26. PubMed ID: 8690051
    [Abstract] [Full Text] [Related]

  • 13. Epratuzumab: targeting B-cell malignancies through CD22.
    Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Ashe M, Fiore JM, Leonard JP.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3991S-4S. PubMed ID: 14506198
    [Abstract] [Full Text] [Related]

  • 14. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ, Gowda A, Czuczman MS.
    Clin Adv Hematol Oncol; 2004 Sep 01; 2(9):606-18. PubMed ID: 16163245
    [Abstract] [Full Text] [Related]

  • 15. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
    Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2003 Dec 15; 9(17):6567-71. PubMed ID: 14695162
    [Abstract] [Full Text] [Related]

  • 16. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 17. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP.
    DiJoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK.
    Cancer Chemother Pharmacol; 2011 Apr 01; 67(4):741-9. PubMed ID: 20521053
    [Abstract] [Full Text] [Related]

  • 18. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.
    Clin Cancer Res; 2004 Aug 15; 10(16):5327-34. PubMed ID: 15328168
    [Abstract] [Full Text] [Related]

  • 19. Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma.
    Yan JS, Chen XY, Li WP, Yang Y, Song ZL.
    Ai Zheng; 2009 Feb 15; 28(2):181-3. PubMed ID: 19550134
    [Abstract] [Full Text] [Related]

  • 20. Therapy of small subcutaneous B-lymphoma xenografts with antibodies conjugated to radionuclides emitting low-energy electrons.
    Michel RB, Rosario AV, Andrews PM, Goldenberg DM, Mattes MJ.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):777-86. PubMed ID: 15701868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.